Related Experiment Videos
Inhaled long acting beta agonists for stable chronic asthma
E H Walters1, J A E Walters, M D P Gibson
1Discipline of Medicine, University of Tasmania Medical School, 43 , Collins Street, PO BOX 252-34, Hobart, 7001, Tasmania, Australia. Haydn.Walters @utas.edu.au
The Cochrane Database of Systematic Reviews
|October 30, 2003
Summary
Long-acting beta-2 agonists improve asthma control, reducing symptoms and enhancing quality of life when used with inhaled corticosteroids. Evidence supports their efficacy in managing chronic asthma.
Area of Science:
- Respiratory Medicine
- Pharmacology
Background:
- Asthma is a prevalent respiratory condition affecting adults and children.
- Short-acting inhaled beta-2 agonists are common for quick relief.
- Long-acting beta-2 agonists (LABAs) were developed as daily symptom controllers alongside inhaled corticosteroids (ICS).
Purpose of the Study:
- To evaluate the benefits or harms of regular long-acting inhaled beta-2 agonist use versus placebo on asthma control.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches and author contact.
- Included studies were of at least two weeks duration, comparing twice-daily LABAs with placebo in chronic asthma patients.
- Data extraction and quality assessment were performed independently by two reviewers.
Main Results:
- Eighty-five RCTs met inclusion criteria, utilizing salmeterol or formoterol.
- LABA treatment showed significant improvements in airway caliber (PEF), reduced symptoms, decreased rescue medication use, and improved quality of life compared to placebo.
- The risk of asthma exacerbations was lower in adults using regular inhaled corticosteroids concurrently.
Conclusions:
- Long-acting beta-2 agonists are effective for controlling chronic asthma.
- Evidence supports their use as an add-on therapy to inhaled corticosteroids, aligning with current treatment guidelines.
- Further research is recommended for children under 12 and mild asthmatics not on ICS.